Christopher Kim bought $50k of APUS
Chairman and CMO at Apimeds Pharmaceuticals US, Inc.. 27,500 shares at an average of $1.83, traded May 13, 2025, filed May 15, 2025.
Score components
- +20RoleChair
- +7Trade size$50k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- 0Price contextNo price history yet
- +15Cluster3 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +5.8%, 3m -8.4%, 6m +61.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001474506-25-000096, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 13, 2025 | POpen-market purchase Common Stock, par value $0.01 per share | +19,770 | $1.82 | $36k | 19,770 | May 15, 2025 |
| May 14, 2025 | POpen-market purchase Common Stock, par value $0.01 per share | +7,730 | $1.86 | $14k | 27,500 | May 15, 2025 |
Related signals
Other insiders at Apimeds Pharmaceuticals US, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 53Moderate | Apimeds Pharmaceuticals US, Inc. | Inscobee Inc. owner | $2.0M 500,000 shares | +34% | |
| 37Weak | Apimeds Pharmaceuticals US, Inc. | Jakap Koo director | $57k 28,500 shares | +5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.